Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.18), $0.43 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $60 thousand versus the consensus estimate of $21 million.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.